Molecular Medicine

Principle Investigator (PI): Pasarat Khongkow, Ph.D. Molecular Oncology (Imperial College London)


Research interests:

Utilization of advanced molecular biology and cell engineering techniques to uncover the  molecular mechanisms of normal cell functions and disease processes, improve diagnosis as well as develop novel therapeutic approaches.

- Molecular Oncology/Cancer Biology

- Cell and Molecular Bioengineering

- Cell based assays

- Cellular Imaging

- Molecular diagnostics

- Aging related diseases

- Identification and validation of novel Biomarker and therapeutic targets

-Targeted therapy

- Cancer Metastasis

- Chemo-radiotherapy resistance in cancer

- Development of cell culture models for anti-cancer drug screening

- Aging, Cellular Senescence, and DNA damage response

- Molecular cosmetics, Anti-aging

 

Research Facility

 

Publications:

  • Limsuwan T, Boonme P, Khongkow P, Amnuaikit T. Ethosomes of Phenylethyl Resorcinol as Vesicular Delivery System for Skin Lightening Applications. BioMed Research International. 2017;2017:12.
  • Khongkow P, Gomes AR, Gong C, Man EPS, Tsang JWH, Zhao F, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene. 2016;35(8):990-1002.
  • Khongkow P, Middleton AK, Wong JP-M, Kandola NK, Kongsema M, Moraes GN, et al. In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs. In: Rueff J, Rodrigues SA, editors. Cancer Drug Resistance: Overviews and Methods. New York, NY: Springer New York; 2016. p. 39-53.
  • Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR, Khongkow P, et al. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene. 2016;35(11):1433-44.
  • de Moraes GN, Khongkow P, Gong C, Yao S, Gomes AR, Ji Z, et al. Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer. Oncogenesis. 2015;4(9):e167.
  • Nestal de Moraes G, Delbue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, et al. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. Cellular Signalling. 2015;27(12):2496-505.
  • Khongkow P, Karunarathna U, Khongkow M, Gong C, Gomes AR, Yague E, et al. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene. 2014;33(32):4144-55.
  • Myatt SS, Kongsema M, Man CWY, Kelly DJ, Gomes AR, Khongkow P, et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene. 2014;33(34):4316-29.
  • Zhao F, Siu MKY, Jiang L, Tam KF, Ngan HYS, Le XF, Khongkow P, et al. Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance. PLoS ONE. 2014;9(11):e113478.
  • Khongkow P, Karunarathna U, Lam E. Abstract A92: The role of FOXM1 and NBS1 in DNA damage-induced senescence and epirubicin resistance. Molecular Cancer Therapeutics. 2013;12(11 Supplement): A92.
  • Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, et al. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene. 2013;32(39):4634-45.
  • Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Khongkow P, Yagüe E, et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 2013;34(7):1476-86.

 


 

 

Last Updated ( Wednesday, 04 May 2016 00:54 )